| Literature DB >> 33093060 |
Matthew Ringer1, Lauren Pischel2, Marwan Mikheal Azar3.
Abstract
Mucormycosis is an invasive mould that can cause aggressive infection, particularly in immunocompromised patients. Though oesophageal mucormycosis is relatively rare, it remains an elusive and devastating manifestation of this disease. The management is also challenging, due to surgical morbidity and contraindications such as thrombocytopenia in immunocompromised hosts. In this report, we present the case of a 60-year-old Lebanese man with newly diagnosed acute myeloid leukaemia who developed oesophageal mucormycosis after induction chemotherapy with idarubicin/cytarabine (7+3). The diagnosis was made when the patient developed febrile neutropenia and odynophagia. CT scan of the chest revealed a thickened oesophagus. Oesophagogastroduodenoscopy with biopsy, histopathology and PCR were performed, resulting in the diagnosis of Rhizopus microsporus The patient was successfully treated with liposomal amphotericin B and salvage posaconazole therapy without surgical intervention. We reviewed the clinical characteristics of the six published oesophageal mucormycosis reports from the literature. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: haematology (incl blood transfusion); infection (gastroenterology); infections; infectious diseases
Mesh:
Substances:
Year: 2020 PMID: 33093060 PMCID: PMC7583061 DOI: 10.1136/bcr-2020-236869
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X